CoChat

Hepatitis C can be cured globally, but at what cost?

Hill, Andrew, Cooke, Graham · 2014 · Science

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

New drugs to cure hepatitis C should be made available at low costs in developing countries

Overview

Integrity signals

Registry

Crossref · 10.1126/science.1257737

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 8 references

Research works printed but not linked: 3

  1. Medivir, 2012 Annual Report, Stockholm (2012), p. 26.
  2. MSF Drug Access Team, Untangling the web of antiretroviral price reductions: 16th edition (Geneva, 2012); www.msfaccess.org/reports.
  3. www.unitaid.org/en/resources/press-centre/releases/1352-unitaid-approves-grants-of-160-million

Cited by

See all 65

Metadata

Authors
Hill, A., & Cooke, G.
Affiliations
  • University of Liverpool (GB)
  • Imperial College London (GB)
Venue
Science
Published
2014-07-11
Volume
345
Issue
6193
Pages
141-142
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W2076417435
Cited by
65
References
8
Citations by year
2025: 2 · 2024: 1 · 2023: 1 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 5 · 2017: 6 · 2016: 16 · 2015: 19 · 2014: 5
Type
journal article
Language
en
Open access
closed
Locations
  • Science (publishedVersion)
  • PubMed (publishedVersion)
Funders
Medical Research Council (MR/K01532X/1)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
hepatitis C, antiviral agents, drug pricing, access to medicines, developing countries, global health, treatment costs
MeSH terms
Sofosbuvir, Simeprevir, Antiviral Agents, Developing Countries, Hepatitis C, Heterocyclic Compounds, 3-Ring, Humans, Sulfonamides, Uridine Monophosphate, Global Health, Drug Costs, Drugs, Generic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatitis C can be cured globally, but at what cost? https://app.cochat.ai/papers/10.1126/science.1257737
The paper
Hill, A., & Cooke, G. (2014). Hepatitis C can be cured globally, but at what cost? Science. https://doi.org/10.1126/science.1257737

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.